Posts
November 15 2023
Client Alert: NLRB Publishes Final Rule Broadening the Joint-Employer Standard
On October 27, 2023, the National Labor Relations Board (“NLRB” or “Board”) published a final rule expanding the standard used to determine Joint-Employer Status under the National Labor Relations Act (“NLRA”). The final rule establishes that, under the NLRA, two or more entities may be considered joint employers of a group of employees if each entity has an employment relationship with the employees, and if the entities share or codetermine one or more of the employees’ essential terms and conditions of employment.
Click here to read the alert.
November 13 2023
Xortx Therapeutics, Inc. announced the commencement of its At the Market offering in the amount of $3,700,000. EG&S acted as counsel to the Manager.
November 13 2023
MAIA Biotechnology, Inc. announced the closing of its Registered Direct offering in the amount of $4,000,000. EG&S acted as counsel to the Placement Agent.
November 06 2023
PaxMedica, Inc. announced the closing of its Public Offering in the amount of $7,000,000. EG&S acted as counsel to the Placement Agent.
November 05 2023
Dolphin Entertainment, Inc. announced the closing of its Public Offering of Common Stock in the amount of $2,310,000. EG&S acted as counsel to the Underwriter.
November 03 2023
Bitfarms Ltd. announced the closing of its Private Placement with U.S Institutional Investors in the amount of CAD$60,000,000. EG&S acted as counsel to the Placement Agent.
November 02 2023
BioCardia, Inc. announced the closing of its Registered Direct offering in the amount of $1,300,000. EG&S acted as counsel to the Placement Agent.
October 31 2023
Vivos Therapeutics, Inc., a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults, announced the pricing of its private placement in the amount of $4,000,000. EGS acted as counsel to Vivos Therapeutics, Inc.